Treats pulmonary arterial hypertension (PAH) (WHO Group 1). ANDA 210473, held by Sun Pharm. Epoprostenol Sodium.
As of Nov 16, 2026, ANDA 210473 (Epoprostenol Sodium), held by Sun Pharm, was first approved by FDA on Jan 15, 2021, with 1 approved supplement and 0 published complete response letters.
Epoprostenol for injection is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2021 | Original application | Approved |
| Epoprostenol SodiumEQ 0.5MG BASE/VIAL · injectable;injection | Epoprostenol Sodium | Rx |
| Epoprostenol SodiumEQ 1.5MG BASE/VIAL · injectable;injection | Epoprostenol Sodium | Rx |
| Jun 3, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 15, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters